Keyphrases
Nuclear Factor Erythroid 2-related Factor 2 (Nrf2)
100%
Drug Development
100%
TAR DNA-binding Protein 43 (TDP-43)
100%
Reporter Expression
100%
Early Biomarker
100%
Degenerative Disease
100%
ESKAPE Pathogens
100%
Methyl
100%
Antimicrobial Activity
100%
Multidrug-resistant
100%
Indole
100%
Synthesized Compounds
100%
Pyrazolone
100%
1,2,3-triazole
100%
Recent Advances
50%
Clinical Trials
50%
Inflammation
50%
Histological Analysis
50%
Reporter Mice
50%
Disease Progression
50%
Neurodegenerative Diseases
50%
HMOX1
50%
Clinical Signs
50%
Cellular Stress
50%
Oxidative Stress
50%
DNA Damage
50%
In Vivo Reporter
50%
Therapeutic Intervention
50%
P53 Pathway
50%
Cellular Damage
50%
Specific Mechanisms
50%
Knoevenagel Condensation
50%
Copper-catalyzed Azide-alkyne Cycloaddition (CuAAC)
50%
1H-1,2,3-triazole
50%
Pyrazole-3-one
50%
Cytotoxicity
50%
Bacterial Infection
50%
Methylene
50%
Cytotoxicity Profile
50%
Fungal Infection
50%
Tolerability
50%
Chloramphenicol
50%
Aspergillus Niger
50%
Gram-negative Bacteria
50%
Vehicle Control
50%
MIC Values
50%
Phenyl
50%
Antifungal Activity
50%
Ampicillin
50%
Fluconazole
50%
Chemistry
Condensation Reaction
100%
Antifungal
100%
MIC
100%
1H-1,2,3-triazole
100%
Chloramphenicol
100%
Pyrazolone
100%
3H-Pyrazole
100%
Ampicillin
100%
Nystatin
100%
Knoevenagel Condensation
100%
Fluconazole
100%
Indole
100%
Cycloaddition
100%
Antimicrobial Agent
100%
Click Chemistry
100%
1,2,3-triazole
100%
Alkyne
100%
Azide
100%
Carbene
100%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Development
100%
Amyotrophic Lateral Sclerosis
100%
Antiinfective Agent
100%
Indole
100%
Infectious Agent
100%
Triazole
100%
Pyrazolone
100%
Cytotoxicity
100%
Bacterial Infection
50%
Nystatin
50%
Tolerability
50%
Mycosis
50%
Antifungal Activity
50%
Carbene
50%
Gram Negative Bacterium
50%
Azide
50%
Candida Albicans
50%
Alkyne
50%
Fluconazole
50%
Antimicrobial Agent
50%
Chloramphenicol
50%
Aspergillus Niger
50%
Pyrazole
50%
Ampicillin
50%
Acinetobacter Baumannii
50%
Protein P53
40%
Cytoprotective Agent
40%
Degenerative Disease
40%
Biological Marker
40%
Inflammation
20%
Disease Exacerbation
20%
Clinical Trial
20%
